Interleukin-23 in the pathogenesis and treatment of psoriasis.

Interleukin-23 in the pathogenesis and treatment of psoriasis.
Skin Therapy Lett. 2015 Apr;20(2):1-4
Authors: Kollipara R, Downing C, Gordon R, Tyring S
Abstract
In the past three decades, major advances have been made in understanding the pathogenesis of psoriasis. The currently accepted theory is that T-cell mediated immune dysregulation triggers keratinocyte hyperproliferation in psoriasis. Recent research indicates that the Th17/interleukin (IL)-23 pathway plays a prominent role in the amplification phase of psoriasis. The discovery of the Th17/ IL-23 pathway provides targets for new drug development. This review focuses on the role of IL-23 in psoriasis pathogenesis and the current therapies targeting IL-23 that are in clinical trials.
PMID: 25807335 [PubMed - in process]

Source: Skin Therapy Letter - March 28, 2015 Category: Dermatology Authors: Kollipara R, Downing C, Gordon R, Tyring S Tags: Skin Therapy Lett Source Type: research